Study of Olverembatinib (HQP1351) in Patients With CP-CML (NCT06423911)
This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia
🩺 Plain-English Summary (8th-Grade Level)
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Who can join: Review the eligibility criteria below.
Location: MD Anderson Cancer Center — Houston, Texas
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (301) 509-0038
Email: kate.shantz@ascentage.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Myeloid Leukemia
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population — Houston, Texas
- Selumetinib and Azacitidine in High Risk Chronic Blood Cancers — Chicago, Illinois
- A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia — New York, New York
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase — Houston, Texas
- Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. — Houston, Texas
Explore by condition: All Chronic Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.